The technology was developed by Prof Tal Dvir from the department of biotechnology and the head of the Nano-technology center at Tel Aviv University and the chief Scientist at Matricelf.
The licensed patent, under examination in the United States and Europe, covers various aspects of the unique technology, which allows simultaneous three-dimensional printing of cells and extracellular components.
Liquid nano-particles, which support and stabilize the liquid printed biological structure, enabling high-resolution printing and maximum accuracy.
Following printing and solidification, the particles are completely removed from the printed structure, leaving it stabilized. Using this technology, the first ever human printed heart was 3D printed at Tel Aviv University in 2019.
Matricelf CEO Dr. Asaf Toker said, "We are happy to sign another collaboration with Tel Aviv University and see this as a strong vote of confidence in the company and its scientific and commercial ability, in the field of tissue engineering, which is the future of medicine. 3D bioprinting is in the forefront of this sector, which is growing by an average of tens of percentages annually and is expected to be worth billions of dollars by 2024. Applying the technology, both in the development of the company, primarily by treating injury to the spinal cord, as well as commercialization to various partners in the sector, significantly increases the potential for growing the value of the company in the foreseeable future and strengthening its status as a leading global player in the sector."